For many years we have been working towards creating a paradigm shift in cancer care, and precision oncology is rapidly evolving, with the potential to revolutionize our current standards and guidelines. But while we have made giant strides in our understanding of the disease, the current approach to biomarker development is still simplistic and fragmented, limiting our ability to understand the underlying biology of the patient’s cancer, tailor treatment to individual patients, monitor treatment response, detect early signs of relapse, and identify potential new targets for therapy. True precision oncology requires a comprehensive and integrated approach to biomarker development to really make a dent.

Read more here.